Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
A peer-reviewed interim analysis of Aroa's MASTRR Registry, published in Advances in Therapy, covered 411 patients and 474 soft tissue defects across 10 US centers and found deep tissue infection in only 0.7% of patients and superficial infection in 2.9%, with no adverse events definitely related to Myriad products. The cohort was highly complex — roughly 59% of patients were ASA Class III or IV — and the authors noted Myriad's infection profile compared very favourably with resorbable synthetic bioscaffolds, where separately published meta-analyses report infection rates of 16% to 25%.
Key figures
- Revenue Yoy
- 54% (FY26 sales growth, cited as context)
- Patients
- 411
- Us centers
- 10
- Registry sites
- 15
- Registry enrolled
- more than 550 patients
- Soft tissue defects
- 474
- Median follow up weeks
- 27
- Asa class iii or iv pct
- 59%
- Deep tissue infection rate
- 0.7%
- Superficial infection rate
- 2.9%
- Registry approved enrollment
- 800
- Median applications per defect
- 1
- Competitor infection rate range
- 16% to 25%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.